Wolverine Asset Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Wolverine Asset Management’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-483	Closed	-$516	–	1493
2016 Q1	$0	Sell	483 -29,000	-98%	-$57.2K	﹤0.01%	1933
2015 Q4	$94K	Buy	29,483 +9,400	+47%	+$45.2K	﹤0.01%	1016
2015 Q3	$125K	Sell	20,083 -77,560	-79%	-$725K	﹤0.01%	1037
2015 Q2	$969K	Buy	97,643 +58,143	+147%	+$509K	0.02%	482
2015 Q1	$291K	Buy	39,500 +36,800	+1,363%	+$248K	0.01%	759
2014 Q4	$14K	Hold	2,700	–	–	﹤0.01%	1707
2014 Q3	$13K	Buy	+2,700	New	+$16.6K	﹤0.01%	1929

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wolverine Asset Management's NWBO Position: Q2 2016 in Review

Wolverine Asset Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2016, closing a stake of 483 shares — an estimated $516 sold.

Wolverine Asset Management first reported a position in NWBO in Q3 2014 and held it in 7 quarters. The position peaked at $969K in Q2 2015. 64 funds tracked by Wall St. Rank hold NWBO as of Q2 2016.

Wolverine Asset Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2016 after selling out during the quarter.
Wolverine Asset Management sold 483 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2016, an estimated $516.
Wolverine Asset Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q3 2014 and held it in 7 quarters.
Wolverine Asset Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $969K in Q2 2015.
64 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2016.

Based on Wolverine Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.